1382 related articles for article (PubMed ID: 33740454)
1. Novel approaches for vaccine development.
Gebre MS; Brito LA; Tostanoski LH; Edwards DK; Carfi A; Barouch DH
Cell; 2021 Mar; 184(6):1589-1603. PubMed ID: 33740454
[TBL] [Abstract][Full Text] [Related]
2. Messenger RNA vaccines against SARS-CoV-2.
Topol EJ
Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
[TBL] [Abstract][Full Text] [Related]
3. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
[No Abstract] [Full Text] [Related]
4. COVID-19 mRNA vaccines.
Huang Q; Zeng J; Yan J
J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
[TBL] [Abstract][Full Text] [Related]
5. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
Shi R; Liu X; Wang Y; Pan M; Wang S; Shi L; Ni B
Hum Vaccin Immunother; 2024 Dec; 20(1):2342592. PubMed ID: 38714327
[TBL] [Abstract][Full Text] [Related]
6. Safety of mRNA-Based Vaccines for SARS CoV-2.
Barda B; Cerny A
Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
[TBL] [Abstract][Full Text] [Related]
7. Introduction to RNA Vaccines Post COVID-19.
Kramps T
Methods Mol Biol; 2024; 2786():1-22. PubMed ID: 38814388
[TBL] [Abstract][Full Text] [Related]
8. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
[TBL] [Abstract][Full Text] [Related]
9. Current and future nanoparticle vaccines for COVID-19.
Vu MN; Kelly HG; Kent SJ; Wheatley AK
EBioMedicine; 2021 Dec; 74():103699. PubMed ID: 34801965
[TBL] [Abstract][Full Text] [Related]
10. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
Granados-Riveron JT; Aquino-Jarquin G
Biomed Pharmacother; 2021 Oct; 142():111953. PubMed ID: 34343897
[TBL] [Abstract][Full Text] [Related]
11. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.
Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
Front Immunol; 2021; 12():679344. PubMed ID: 34305909
[TBL] [Abstract][Full Text] [Related]
12. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.
Yang R; Deng Y; Huang B; Huang L; Lin A; Li Y; Wang W; Liu J; Lu S; Zhan Z; Wang Y; A R; Wang W; Niu P; Zhao L; Li S; Ma X; Zhang L; Zhang Y; Yao W; Liang X; Zhao J; Liu Z; Peng X; Li H; Tan W
Signal Transduct Target Ther; 2021 May; 6(1):213. PubMed ID: 34059617
[TBL] [Abstract][Full Text] [Related]
13. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?
Doerfler W
Virus Res; 2021 Sep; 302():198466. PubMed ID: 34087261
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 evolution and vaccines: cause for concern?
Williams TC; Burgers WA
Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
[No Abstract] [Full Text] [Related]
16. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.
Mulhern JG; Fadia A; Patel R; Ficociello LH; Willetts J; Dahne-Steuber IA; Pollan MC; Mullon C; DeLisi J; Johnson C; Mysayphonh C; Kossmann RJ; Anger MS; Hymes JL
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1720-1722. PubMed ID: 34312162
[No Abstract] [Full Text] [Related]
17. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
18. Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.
Zimmermann L; Erbar S
Methods Mol Biol; 2024; 2786():135-144. PubMed ID: 38814392
[TBL] [Abstract][Full Text] [Related]
19. What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases.
Park JK; Lee EB; Winthrop KL
Ann Rheum Dis; 2024 May; 83(6):687-695. PubMed ID: 38413167
[TBL] [Abstract][Full Text] [Related]
20. Addressing the Cold Reality of mRNA Vaccine Stability.
Crommelin DJA; Anchordoquy TJ; Volkin DB; Jiskoot W; Mastrobattista E
J Pharm Sci; 2021 Mar; 110(3):997-1001. PubMed ID: 33321139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
